Ingalls Kerry D. 4
4 · Poseida Therapeutics, Inc. · Filed Mar 1, 2022
Insider Transaction Report
Form 4
Ingalls Kerry D.
Chief Operating Officer
Transactions
- Award
Employee Stock Option (Right to Buy)
2022-03-01+72,568→ 72,568 totalExercise: $3.42Exp: 2032-02-29→ Common Stock (72,568 underlying) - Award
Common Stock
2022-03-01+50,000→ 52,000 total
Footnotes (2)
- [F1]Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
- [F2]12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.